Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Selection of a trioxaquine as an antimalarial drug candidate.

Coslédan F, Fraisse L, Pellet A, Guillou F, Mordmüller B, Kremsner PG, Moreno A, Mazier D, Maffrand JP, Meunier B.

Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17579-84. doi: 10.1073/pnas.0804338105. Epub 2008 Nov 5.

2.

Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.

Janiak P, Poirier B, Bidouard JP, Cadrouvele C, Pierre F, Gouraud L, Barbosa I, Dedio J, Maffrand JP, Le Fur G, O'Connor S, Herbert JM.

Kidney Int. 2007 Dec;72(11):1345-57. Epub 2007 Sep 19.

3.

Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.

Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, Arnone M, Croci T, Soubrié P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, Le Fur G, Herbert JM, Bensaid M.

Hepatology. 2007 Jul;46(1):122-9.

PMID:
17526015
4.

In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum.

Daher W, Pelinski L, Klieber S, Sadoun F, Meunier V, Bourrié M, Biot C, Guillou F, Fabre G, Brocard J, Fraisse L, Maffrand JP, Khalife J, Dive D.

Drug Metab Dispos. 2006 Apr;34(4):667-82. Epub 2006 Jan 13.

PMID:
16415117
5.

SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor.

Serradeil-Le Gal C, Valette G, Foulon L, Germain G, Advenier C, Naline E, Bardou M, Martinolle JP, Pouzet B, Raufaste D, Garcia C, Double-Cazanave E, Pauly M, Pascal M, Barbier A, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2004 Apr;309(1):414-24. Epub 2004 Jan 13.

PMID:
14722330
6.

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrié P.

Mol Pharmacol. 2003 Apr;63(4):908-14.

PMID:
12644592
7.

SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.

Emonds-Alt X, Proietto V, Steinberg R, Oury-Donat F, Vigé X, Vilain P, Naline E, Daoui S, Advenier C, Le Fur G, Maffrand JP, Soubrié P, Pascal M.

J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9.

PMID:
12438541
8.

Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.

Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G.

Prog Brain Res. 2002;139:197-210. Review.

PMID:
12436936
9.

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.

Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P.

Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R345-53. Epub 2002 Oct 24.

10.

Structure and stereochemistry of the active metabolite of clopidogrel.

Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, Picard C.

Drug Metab Dispos. 2002 Nov;30(11):1288-95.

PMID:
12386137
11.

Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors.

Landi M, Croci T, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Manara L.

Eur J Pharmacol. 2002 Aug 16;450(1):77-83.

PMID:
12176112
12.

Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist.

Emonds-Alt X, Proietto V, Steinberg R, Advenier C, Daoui S, Naline E, Gueudet C, Michaud JC, Oury-Donat F, Poncelet M, Vilain P, Le Fur G, Maffrand JP, Soubrié P, Pascal M.

Can J Physiol Pharmacol. 2002 May;80(5):482-8.

PMID:
12056557
13.

Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon.

Manara L, Croci T, Guagnini F, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Mukenge S, Ferla G.

Dig Liver Dis. 2002 Apr;34(4):262-9.

PMID:
12038810
14.

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P.

Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6370-5. Epub 2002 Apr 16.

15.

[Design and birth of drugs].

Maffrand JP, Lehner JP, Le Fur G.

Rev Prat. 2002 Mar 1;52(5):482-5. French.

PMID:
11949498
17.

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.

Gully D, Geslin M, Serva L, Fontaine E, Roger P, Lair C, Darre V, Marcy C, Rouby PE, Simiand J, Guitard J, Gout G, Steinberg R, Rodier D, Griebel G, Soubrie P, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Apr;301(1):322-32.

PMID:
11907190
18.

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30.

PMID:
11861823
19.

Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries.

Anderson HV, McNatt J, Clubb FJ, Herman M, Maffrand JP, DeClerck F, Ahn C, Buja LM, Willerson JT.

Circulation. 2001 Nov 6;104(19):2331-7.

PMID:
11696474
20.

A nonpeptide vasopressin V(1a) receptor antagonist, SR 49059, does not prevent cisplatin-induced emesis in piglets.

Grélot L, Girod V, Dapzol J, Maffrand JP, Serradeil-Le Gal C.

Fundam Clin Pharmacol. 2001 Jun;15(3):189-200.

PMID:
11468030
21.

Selective blockade of vasopressin V2 receptors reveals significant V2-mediated water reabsorption in Brattleboro rats with diabetes insipidus.

Pouzet B, Serradeil-Le Gal C, Bouby N, Maffrand JP, Le Fur G, Bankir L.

Nephrol Dial Transplant. 2001 Apr;16(4):725-34.

PMID:
11274265
22.

Identification and biological activity of the active metabolite of clopidogrel.

Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM.

Thromb Haemost. 2000 Nov;84(5):891-6.

PMID:
11127873
23.

Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.

Serradeil-Le Gal C, Raufaste D, Double-Cazanave E, Guillon G, Garcia C, Pascal M, Maffrand JP.

Kidney Int. 2000 Oct;58(4):1613-22.

24.

Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.

Jiménez W, Gal CS, Ros J, Cano C, Cejudo P, Morales-Ruiz M, Arroyo V, Pascal M, Rivera F, Maffrand JP, Rodés J.

J Pharmacol Exp Ther. 2000 Oct;295(1):83-90.

PMID:
10991964
25.

Functional assessment of beta adrenoceptor subtypes in human colonic circular and longitudinal (taenia coli) smooth muscle.

Manara L, Croci T, Aureggi G, Guagnini F, Maffrand JP, Le Fur G, Mukenge S, Ferla G.

Gut. 2000 Sep;47(3):337-42.

26.

Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension.

Lacheretz F, Barbier A, Serradeil-Le Gal C, Elena PP, Maffrand JP, Le Fur G.

J Ocul Pharmacol Ther. 2000 Jun;16(3):203-16.

PMID:
10872918
27.

Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes.

Serradeil-Le Gal C, Lafontan M, Raufaste D, Marchand J, Pouzet B, Casellas P, Pascal M, Maffrand JP, Le Fur G.

FEBS Lett. 2000 Jun 16;475(2):150-6.

28.

The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.

Bourrié B, Bribes E, Esclangon M, Garcia L, Marchand J, Thomas C, Maffrand JP, Casellas P.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12855-9.

29.

The cloned guinea pig neuropeptide Y receptor Y1 conforms to other mammalian Y1 receptors.

Berglund MM, Holmberg SK, Eriksson H, Gedda K, Maffrand JP, Serradeil-Le Gal C, Chhajlani V, Grundemar L, Larhammar D.

Peptides. 1999;20(9):1043-53.

PMID:
10499421
30.

In vitro functional evidence of different neurotensin-receptors modulating the motor response of human colonic muscle strips.

Croci T, Aureggi G, Guagnini F, Manara L, Gully D, Fur GL, Maffrand JP, Mukenge S, Ferla G, Ferrara P, Chalon P, Vita N.

Br J Pharmacol. 1999 Aug;127(8):1922-8.

31.

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.

Bignon E, Alonso R, Arnone M, Boigegrain R, Brodin R, Gueudet C, Héaulme M, Keane P, Landi M, Molimard JC, Olliero D, Poncelet M, Seban E, Simiand J, Soubrié P, Pascal M, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 1999 May;289(2):752-61.

PMID:
10215649
32.

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.

Bignon E, Bachy A, Boigegrain R, Brodin R, Cottineau M, Gully D, Herbert JM, Keane P, Labie C, Molimard JC, Olliero D, Oury-Donat F, Petereau C, Prabonnaud V, Rockstroh MP, Schaeffer P, Servant O, Thurneyssen O, Soubrié P, Pascal M, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 1999 May;289(2):742-51.

PMID:
10215648
33.

Binding of the non-peptide vasopressin V1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study.

Tribollet E, Raufaste D, Maffrand J, Serradeil-Le Gal C.

Neuroendocrinology. 1999 Feb;69(2):113-20.

PMID:
9986924
34.

In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum.

Croci T, Manara L, Aureggi G, Guagnini F, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Mukenge S, Ferla G.

Br J Pharmacol. 1998 Dec;125(7):1393-5.

35.

Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells.

Vita N, Oury-Donat F, Chalon P, Guillemot M, Kaghad M, Bachy A, Thurneyssen O, Garcia S, Poinot-Chazel C, Casellas P, Keane P, Le Fur G, Maffrand JP, Soubrie P, Caput D, Ferrara P.

Eur J Pharmacol. 1998 Nov 6;360(2-3):265-72.

PMID:
9851594
36.

SR 121787, a new orally active fibrinogen receptor antagonist.

Savi P, Badorc A, Lalé A, Bordes MF, Bornia J, Labouret C, Bernat A, de Cointet P, Hoffmann P, Maffrand JP, Herbert JM.

Thromb Haemost. 1998 Sep;80(3):469-76.

PMID:
9759629
37.

The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor.

Mazella J, Zsürger N, Navarro V, Chabry J, Kaghad M, Caput D, Ferrara P, Vita N, Gully D, Maffrand JP, Vincent JP.

J Biol Chem. 1998 Oct 9;273(41):26273-6.

38.

In vitro characterization of tachykinin NK2-receptors modulating motor responses of human colonic muscle strips.

Croci T, Aureggi G, Manara L, Emonds-Alt X, Le Fur G, Maffrand JP, Mukenge S, Ferla G.

Br J Pharmacol. 1998 Jul;124(6):1321-7.

39.
40.

The non-peptide neuroprotective agents SR 57746A interacts with neurotrophin 3 to induce differentiation in the PC12 cell-line.

Fournier J, Boutot G, Keane PE, Maffrand JP, Le Fur G, Soubrié P.

J Pharm Pharmacol. 1998 Mar;50(3):323-7.

PMID:
9600726
41.

Biochemical and pharmacological activities of SR 144190, a new potent non-peptide tachykinin NK2 receptor antagonist.

Emonds-Alt X, Advenier C, Cognon C, Croci T, Daoui S, Ducoux JP, Landi M, Naline E, Neliat G, Poncelet M, Proietto V, Van Broeck D, Vilain P, Soubrié P, Le Fur G, Maffrand JP, Brelière JC.

Neuropeptides. 1997 Oct;31(5):449-58.

PMID:
9413022
43.

Purification and characterization of the human SR 31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase.

Jbilo O, Vidal H, Paul R, De Nys N, Bensaid M, Silve S, Carayon P, Davi D, Galiègue S, Bourrié B, Guillemot JC, Ferrara P, Loison G, Maffrand JP, Le Fur G, Casellas P.

J Biol Chem. 1997 Oct 24;272(43):27107-15.

44.

Effects of divalent cations and of a calcimimetic on adrenocorticotropic hormone release in pituitary tumor cells.

Ferry S, Chatel B, Dodd RH, Lair C, Gully D, Maffrand JP, Ruat M.

Biochem Biophys Res Commun. 1997 Sep 29;238(3):866-73.

PMID:
9325183
45.

A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.

Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le Fur G, Casellas P.

J Biol Chem. 1997 Aug 29;272(35):22330-9.

46.

Role of tachykinins in castor oil diarrhoea in rats.

Croci T, Landi M, Emonds-Alt X, Le Fur G, Maffrand JP, Manara L.

Br J Pharmacol. 1997 Jun;121(3):375-80.

47.

Negative modulation of nitric oxide production by neurotensin as a putative mechanism of the diuretic action of SR 48692 in rats.

Croci T, Landi M, Gully D, Maffrand JP, Le Fur G, Manara L.

Br J Pharmacol. 1997 Apr;120(7):1312-8.

48.

Characterization and localization of leptin receptors in the rat kidney.

Serradeil-Le Gal C, Raufaste D, Brossard G, Pouzet B, Marty E, Maffrand JP, Le Fur G.

FEBS Lett. 1997 Mar 10;404(2-3):185-91.

49.

Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.

Gully D, Labeeuw B, Boigegrain R, Oury-Donat F, Bachy A, Poncelet M, Steinberg R, Suaud-Chagny MF, Santucci V, Vita N, Pecceu F, Labbé-Jullié C, Kitabgi P, Soubrié P, Le Fur G, Maffrand JP.

J Pharmacol Exp Ther. 1997 Feb;280(2):802-12.

PMID:
9023294
50.

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D, Jard S, Vilain P, Garcia C, Marty E, Raufaste D, Brossard G, Nisato D, Maffrand JP, Le Fur G.

J Clin Invest. 1996 Dec 15;98(12):2729-38.

Supplemental Content

Loading ...
Support Center